Teva Pharmaceutical Industries Limited Financials

Market Capitalization ₪68.99 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	2940.00
Forward PE	21.98
Price to Sales TTM	₪4.11
Price to Book MRQ	₪1137.49
Enterprise to Revenue	5.08
Enterprise to EBITDA	17.82

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-5.72%
Operating Margin	23.18%
Return on Assets TTM	5.56%
Return on Equity TTM	-17.52%

Income Statement

Revenue TTM	₪15,845,000,000
Revenue per Share TTM	₪14.88
Quarterly Revenue Growth	12.50%
Gross Profit TTM	₪7,645,000,000
EBITDA	₪4,720,000,000
Net Income to Common TTM	₪-559,000,000
Diluted EPS TTM	₪-3.09
Quarterly Earnings Growth YoY	12.49%

Balance Sheet

Total Cash MRQ	₪1,497,000,000
Total Cash per Share MRQ	₪2.93
Total Debt MRQ	₪
Total Debt to Equity MRQ	301.93
Current Ratio MRQ	0.89
Book Value per Share MRQ	₪5.35

Cash Flow

Operating Cash Flow TTM	₪331,000,000
Levered Free Cash Flow TTM	₪9,456,000,000

TEVA Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	1,133,049,984
Float Shares	1,126,319,896
Avg 10 Volume	1,290,765
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	0.56%
% Held by Institutions	14.20%

Stock Price Summary

Beta	0.87
Fifty Two Week Low	₪4023.00
Fifty Two Week High	₪8431.00
Fifty Two Week Change	43.80%
Day 50 MA	₪6557.18
Day 200 MA	₪5962.16

Dividends and Splits

Forward Annual Dividend Rate	₪34.00
Forward Annual Dividend Yield	0.44%
Trailing Annual Dividend Rate	₪85.00
Trailing Annual Dividend Yield	1.10%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2017-11-28
Last Split Factor
Last Split Date	2004-06-27